1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Angiotensin Converting Enzyme (ACE) Inhibitors Market
2.2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2023 (US$ Million)
2.3. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2023 (US$ Million)
2.4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Competitive Analysis
3.1. Market Positioning of Key Angiotensin Converting Enzyme (ACE) Inhibitors Market Vendors
3.2. Strategies Adopted by Angiotensin Converting Enzyme (ACE) Inhibitors Market Vendors
3.3. Key Industry Strategies
4. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Benazepri
5.3.2. Captopril
5.3.3. Enalapril
5.3.4. Fosinopril
5.3.5. Lisinopril
5.3.6. Moexipril
5.3.7. Perindopril
5.3.8. Quinapril
5.3.9. Ramipril
5.3.10. Trandolapril
5.3.11. Combination ACE Inhibitors

6. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hypertension
6.3.2. Coronary Artery Diseases
6.3.3. Heart Failure
6.3.4. Myocardial Infarction
6.3.5. Diabetes
6.3.6. Chronic Kidney Disorders
6.3.7. Others (Scleroderma, Migraine and others)


7. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
7.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
7.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.2.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
7.4.1.3.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)

8. UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
8.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.2.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.3.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.4.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.5.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
8.4.1.6.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)

9. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
9.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.2.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.3.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.4.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.5.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
9.4.1.6.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)

10. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
10.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
10.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.2.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
10.4.1.3.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)

11. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
11.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
11.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.1.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.2.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2022-2032, USD (Million)
11.4.1.3.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2022-2032, USD (Million)

12. Company Profile
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Pfizer, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Merck & Co.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Astra Zeneca plc
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Jhonson and Johnson Limited
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Eli Lilly and Company
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Sanofi SA
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Bristol-Myers Squibb Company
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Bayer AG
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. GlaxoSmithKline plc
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Teva Pharmaceutical Industries Ltd.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives